368 related articles for article (PubMed ID: 25319061)
21. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
23. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
24. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP;
Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636
[TBL] [Abstract][Full Text] [Related]
25. miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou JV; Rossi S; Jensen BV; Nielsen DL; Pfeiffer P; Høgdall E; Yilmaz M; Tejpar S; Delorenzi M; Kruhøffer M; Johansen JS
PLoS One; 2014; 9(6):e99886. PubMed ID: 24940606
[TBL] [Abstract][Full Text] [Related]
26. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Cohn AL; Tabernero J; Maurel J; Nowara E; Sastre J; Chuah BYS; Kopp MV; Sakaeva DD; Mitchell EP; Dubey S; Suzuki S; Hei YJ; Galimi F; McCaffery I; Pan Y; Loberg R; Cottrell S; Choo SP
Ann Oncol; 2013 Jul; 24(7):1777-1785. PubMed ID: 23510984
[TBL] [Abstract][Full Text] [Related]
27. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
28. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
29. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
30. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
31. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
32. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M
Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408
[TBL] [Abstract][Full Text] [Related]
33. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM; Guren T; Glimelius B; Pfeiffer P; Sorbye H; Pyrhonen S; Sigurdsson F; Kure E; Ikdahl T; Skovlund E; Fokstuen T; Hansen F; Hofsli E; Birkemeyer E; Johnsson A; Starkhammar H; Yilmaz MK; Keldsen N; Erdal AB; Dajani O; Dahl O; Christoffersen T
J Clin Oncol; 2012 May; 30(15):1755-62. PubMed ID: 22473155
[TBL] [Abstract][Full Text] [Related]
34. Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Sobrero A; Lenz HJ; Eng C; Scheithauer W; Middleton G; Chen W; Esser R; Nippgen J; Burris H
Oncologist; 2021 Feb; 26(2):e261-e269. PubMed ID: 33191588
[TBL] [Abstract][Full Text] [Related]
35. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X; Pericay C; Alonso-Espinaco V; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Gascón P; Castellví-Bel S; Maurel J
Tumour Biol; 2011 Apr; 32(2):417-24. PubMed ID: 21104178
[TBL] [Abstract][Full Text] [Related]
36. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
37. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
[TBL] [Abstract][Full Text] [Related]
38. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
39. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147.
Huang J; Nair SG; Mahoney MR; Nelson GD; Shields AF; Chan E; Goldberg RM; Gill S; Kahlenberg MS; Quesenberry JT; Thibodeau SN; Smyrk TC; Grothey A; Sinicrope FA; Webb TA; Farr GH; Pockaj BA; Berenberg JL; Mooney M; Sargent DJ; Alberts SR;
Clin Colorectal Cancer; 2014 Jun; 13(2):100-9. PubMed ID: 24512953
[TBL] [Abstract][Full Text] [Related]
40. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
